Medical Treatment and Clinical Protocols
At a Glance
For children with GLUD1-related HI/HA syndrome, diazoxide is usually effective, but it requires individualized diuretic therapy and close monitoring for fluid buildup, high blood pressure in the lungs, and low white blood cell counts. Severe low blood sugar needs emergency hospital care.
Managing HI/HA syndrome typically involves a shift from emergency “rescue” mode to a long-term medical routine. Because the GLUD1 variant makes the pancreas overactive, the goal of treatment is to find the right balance of medication to “quiet” the insulin-producing cells while protecting the rest of the body [1].
Important Safety Warning: Never increase, decrease, or stop diazoxide, chlorothiazide, or any prescribed medication without direct instructions from your prescribing doctor.
First-Line Treatment: Diazoxide
The standard of care for children with HI/HA is a medication called diazoxide [2]. It works by acting directly on the “gates” of the insulin-producing cells in the pancreas, keeping them open so that insulin is not released inappropriately [1].
Research shows that almost all children with the GLUD1 variant respond very well to this treatment [2][3]. In many cases, if a child is also on a leucine-restricted diet, they may even be able to use a lower dose of the medication to keep their blood sugar stable [2].
Diazoxide dosing is highly individualized. While traditional doses range from 5 to 15 mg/kg/day, your doctor may start your child at a lower dose (around 2 to 5 mg/kg/day) to see how they respond while minimizing side effects [1].
Dosing and the Necessity of Diuretics
A critical part of the protocol is the co-administration of a diuretic, most commonly chlorothiazide [4][5]. Diazoxide tells the kidneys to hold onto salt and water, which can lead to dangerous fluid buildup. The diuretic helps the body “flush” this extra fluid out [5].
Your clinical team will carefully prescribe and monitor your child’s fluid intake, electrolytes, weight, and renal function. Fluid plans must be strictly individualized based on age, weight, heart function, and illness; families should not restrict fluids on their own without direct supervision, as inappropriate restriction can cause severe dehydration [6][7].
Monitoring for Side Effects
While diazoxide is effective, it requires careful monitoring according to your local specialist protocol for both common and rare side effects:
- Hypertrichosis (Common): Many children experience increased body hair growth [8]. While this can be distressing for parents, it is not medically dangerous and is usually reversible if the medication is stopped [9].
- Fluid Retention and Edema: Swelling in the face or limbs can occur, often in the first two months of treatment [9]. Rapid weight gain or swelling warrants a call to your doctor.
- Pulmonary Hypertension (Urgent Risk): Diazoxide can cause high blood pressure in the lungs [4][6]. This is a medical emergency. Specialist protocols generally require a baseline echocardiogram (heart ultrasound) before starting treatment, with an early follow-up (often within 1 to 2 weeks) to ensure the heart is handling the medication safely [6][10]. Seek urgent medical care if your child exhibits worsening or rapid breathing, a bluish color (cyanosis), poor feeding, unusual lethargy, or edema.
- Neutropenia: Some children develop a low white blood cell count (neutropenia), which can make them more prone to infections [4][8]. Regular blood tests are necessary to monitor this [4].
Emergency Hospital Protocol
If your child experiences a severe “low” that cannot be managed at home, the hospital protocol involves rapid, high-concentration interventions to protect the brain [11]:
- IV Dextrose: Concentrated sugar is delivered directly into the vein to raise blood sugar levels immediately [11].
- IV Glucagon: If blood sugar is still hard to stabilize, a continuous infusion of glucagon may be used to help the liver release its own sugar stores [12][13].
When Treatment Isn’t Working
Because GLUD1-related HI/HA is usually responsive to diazoxide, apparent nonresponse should prompt an urgent reassessment. If diazoxide does not work (diazoxide-unresponsive disease), your child should be referred to a specialized Congenital Hyperinsulinism (CHI) center [14].
The specialist team will first review the diagnosis, medication adherence, dosing, and dietary factors. If true unresponsiveness is confirmed, they may explore individualized second-line medical options like octreotide or lanreotide [15][16]. While advanced imaging, such as an 18F-DOPA PET/CT scan, and focal surgery are common pathways for certain forms of diazoxide-unresponsive CHI, focal surgery is not routine for GLUD1-HI/HA and carries risks such as diabetes and pancreatic insufficiency [17][18]. A specialized center provides the most precise care for these complex situations [14].
Common questions in this guide
What medicine is usually started for children with HI/HA syndrome?
Why is a diuretic often prescribed with diazoxide?
What tests and monitoring are needed when a child starts diazoxide?
Which symptoms could signal a serious diazoxide side effect?
How is severe low blood sugar treated in the hospital?
What happens if diazoxide does not control HI/HA syndrome?
Get notified when new evidence is published on Hyperinsulinism-hyperammonemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review.
Wong T, Chan D, Chua C, et al.
Frontiers in pharmacology 2026; (17()):1781424 doi:10.3389/fphar.2026.1781424.
PMID: 41982675 - 2
Clinical and Molecular Spectrum of Glutamate Dehydrogenase Gene Defects in 26 Chinese Congenital Hyperinsulinemia Patients.
Su C, Liang XJ, Li WJ, et al.
Journal of diabetes research 2018; (2018()):2802540 doi:10.1155/2018/2802540.
PMID: 30306091 - 3
Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1.
Aftab S, Gubaeva D, Houghton JAL, et al.
Endocrine connections 2023; (12(4)).
PMID: 35951311 - 4
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Herrera A, Vajravelu ME, Givler S, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(12)):4365-4372 doi:10.1210/jc.2018-01613.
PMID: 30247666 - 5
Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.
Timlin MR, Black AB, Delaney HM, et al.
Pediatric cardiology 2017; (38(6)):1247-1250 doi:10.1007/s00246-017-1652-3.
PMID: 28642988 - 6
Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.
Chen SC, Dastamani A, Pintus D, et al.
Clinical endocrinology 2019; (91(6)):770-775 doi:10.1111/cen.14096.
PMID: 31520536 - 7
Trisomy 13 as a risk factor for pulmonary hypertension induced by diazoxide.
Ishikawa K, Nakao H, Shinjo D, et al.
Annals of pediatric cardiology 2025; (18(4)):351-356 doi:10.4103/apc.apc_65_25.
PMID: 41725869 - 8
Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.
Chen X, Feng L, Yao H, et al.
PloS one 2021; (16(2)):e0246463 doi:10.1371/journal.pone.0246463.
PMID: 33571197 - 9
Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey).
Fukutomi M, Shimodera M, Maeda Y, et al.
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2018; (27(3)):131-143 doi:10.1297/cpe.27.131.
PMID: 30083030 - 10
Pericardial Effusion Associated with Diazoxide Treatment for Congenital Hyperinsulinism.
Hastings LA, Preddy J, McCready M, et al.
Hormone research in paediatrics 2020; (93(3)):206-211 doi:10.1159/000507624.
PMID: 32580193 - 11
Congenital Hyperinsulinism - Notes for the General Pediatrician.
Estebanez MS, Worth C, Banerjee I
Indian pediatrics 2024; (61(6)):578-584.
PMID: 38584412 - 12
The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism.
Hawkes CP, Lado JJ, Givler S, De Leon DD
JIMD reports 2019; (45()):45-50 doi:10.1007/8904_2018_140.
PMID: 30311139 - 13
Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series.
Salomon-Estebanez M, Yau D, Dunne MJ, et al.
Frontiers in endocrinology 2020; (11()):441 doi:10.3389/fendo.2020.00441.
PMID: 33013678 - 14
Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.
Stanley CA
The Journal of clinical endocrinology and metabolism 2016; (101(3)):815-26 doi:10.1210/jc.2015-3651.
PMID: 26908106 - 15
Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
Hosokawa Y, Kawakita R, Yokoya S, et al.
Endocrine journal 2017; (64(9)):867-880 doi:10.1507/endocrj.EJ17-0024.
PMID: 28701683 - 16
Octreotide efficacy and safety in children with hyperinsulinism: evidence from two Chinese centers.
Ni J, Cao B, Zeng H, et al.
European journal of pediatrics 2024; (184(1)):33 doi:10.1007/s00431-024-05884-x.
PMID: 39565408 - 17
Visual interpretation, not SUV ratios, is the ideal method to interpret 18F-DOPA PET scans to aid in the cure of patients with focal congenital hyperinsulinism.
Garg PK, Putegnat B, Truong L, et al.
PloS one 2020; (15(10)):e0241243 doi:10.1371/journal.pone.0241243.
PMID: 33108363 - 18
18F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.
States LJ, Davis JC, Hamel SM, et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021; (62(Suppl 2)):51S-56S doi:10.2967/jnumed.120.246033.
PMID: 34230074
This page explains treatment and safety monitoring for children with HI/HA syndrome for educational purposes only and does not replace medical advice. Do not change medication or fluid plans without direct instructions from your child's prescribing team.